Sources say brand and generic drug trade groups have agreed in principle on a deal that couples a tweaked version of the generic-backed bill to stop brands from using drug safety requirements to delay competition with brand-backed Part D bills to reduce brands' contribution to beneficiaries' donut-hole costs and avert the so-called coverage gap "cliff." Patients for Affordable Drugs describes the changes in brands' donut-hole contribution as a "fast-moving deal" that would benefit brands at the expense of patients, but...